Compare iShares Core MSCI EAFE ETF (IEFA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Core MSCI EAFE ETF trades at $96.36, while Vertex Pharmaceuticals Incorporated trades at $480 (market cap $121.95B). The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| IEFA | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $98.56 | $529.59 |
52-Week Low | $81.70 | $366.54 |
Market Cap | — | $121.95B |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $95.57, down 0.71% today amid a bearish technical signal. The ETF focuses on developed international equities excluding the U.S. and Canada, offering a 3.30% dividend yield with a low 0.07% expense ratio. Recent news highlights its role in diversification away from S&P 500 concentration risks. Key support and resistance levels are tightly clustered around $96-$97.
The outlook remains mixed; IEFA provides cost-effective exposure to stable international markets but faces headwinds from currency fluctuations and central bank policy shifts. Its bearish technical trend and neutral oscillators suggest near-term consolidation, while long-term investors may value its dividend income and geographic diversification benefits.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
